



59/284009  
4-5-99

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 48/00, 47/48</b>	A1	(11) International Publication Number: <b>WO 98/15294</b> (43) International Publication Date: 16 April 1998 (16.04.98)
(21) International Application Number: <b>PCT/GB97/02709</b>		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 8 October 1997 (08.10.97)		
(30) Priority Data:		
9620952.3 9 October 1996 (09.10.96) GB		
9701975.6 30 January 1997 (30.01.97) GB		
9703670.1 21 February 1997 (21.02.97) GB		
(71) Applicant (for all designated States except US): THE UNIVERSITY OF SHEFFIELD [GB/GB]; Western Bank, Sheffield, South Yorkshire S10 2TN (GB).		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(72) Inventors; and		
(75) Inventors/Applicants (for US only): LEWIS, Claire, Elizabeth [GB/GB]; The University of Sheffield Medical School, Dept. of Pathology, Beech Hill Road, Sheffield S10 2RX (GB). HARRIS, Adrian, Llewlyn [GB/GB]; Isis Innovation Limited, 2 South Parks Road, Oxford OX1 3UB (GB). MARSHALL, Julian, Malcolm [GB/GB]; Oxford Bioresearch Laboratory, Magdalen Centre, Oxford Science Park, Oxford OX4 4GA (GB).		
(74) Agent: WILLIAM JONES (YORK); The Crescent, 54 Blossom Street, York YO2 2AP (GB).		

(54) Title: MONONUCLEAR PHAGOCYTES IN THERAPEUTIC DRUG DELIVERY

## (57) Abstract

The invention relates to the exploitation of the migratory behaviour of mononuclear phagocytes with a view to targeting therapeutic drug delivery. The invention therefore concerns the attachment or incorporation of a therapeutic agent to or into a mononuclear phagocyte and the subsequent migration of the mononuclear phagocyte to a target area.